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Background. Acute renal failure (ARF) is a cause of renal
dysfunction in human immunodeficiency virus (HIV)-infected
patients. Its incidence and causes have not been studied since the
introduction of highly active antiretroviral therapy (HAART)
in HIV ambulatory patients.
Methods. This is a prospective cohort study of 754 HIV pa-
tients, 18 years or older, seen at a university-based infectious
disease clinic between 2000 and 2002. ARF was identified using
proportional increases in serum creatinine from baseline and
by chart review. Clinical conditions were assessed at the time of
the ARF event. ARF incidence rates (IR) were calculated by
dividing the number of events by person time at risk. To com-
pare patients with and without ARF, t test or chi-square test
were used.
Results. Patient’s mean age was 40 years; 68% were male and
61% were black. One hundred-eleven ARF events occurred
in 71 subjects (IR 5.9 per 100 person-years; 95% CI 4.9, 7.1).
ARF was more common in men, in those with CD4 cell count
<200 cells/mm3, and HIV RNA levels >10,000 copies/mL.
These patients more often had acquired immunodeficiency syn-
drome (AIDS), hepatitis C infection (HCV), and have received
HAART. ARF was mainly community-acquired, due to prere-
nal causes or acute tubular necrosis, and associated with oppor-
tunistic infections and drugs. Liver disease was a cause of ARF
in HCV-infected patients.
Conclusion. ARF is common in ambulatory HIV patients.
Immunosuppression, infection, and HCV are important condi-
tions associated with ARF in the post-HAART era.
Renal abnormalities are common among human im-
munodeficiency virus (HIV)-infected patients, resulting
in increased morbidity and mortality [1]. One of the most
common causes of renal dysfunction in HIV-infected pa-
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tients is acute renal failure (ARF). ARF is often seen
in patients with severe immunodeficiency and acquired
immunodeficiency syndrome (AIDS)-defining clinical
conditions [2–6]. Patients with advanced HIV disease re-
quire frequent hospitalizations and multiple drug treat-
ments, which are well-established contributing factors to
developing ARF. Studies of hospitalized patients under-
going renal biopsy have shown that acute tubular necrosis
(ATN) and thrombotic microangiopathies are the most
common findings of ARF in immunosupressed patients
[3, 6]. However, since the advent of highly active an-
tiretroviral therapy (HAART), morbidity and mortality
from HIV infection has decreased substantially [7, 8] and
the hospitalization rate for AIDS-defining conditions has
declined [9, 10]. Consequently, comorbid chronic condi-
tions associated with kidney dysfunction such as hyper-
tension and diabetes, and coinfections such as hepatitis C
infection (HCV) are increasingly important in the care
of HIV-infected patients. HIV-infected individuals are
also often exposed to a variety of potential nephrotoxic
drugs for treatment of HIV, coinfections, or comorbidi-
ties. Therefore, it is expected that the risk profile of pa-
tients presenting with ARF and its causes has changed
since the introduction of HAART into routine HIV clin-
ical care.
Few studies have addressed the incidence of ARF in
the post-HAART era. Studies have relied on hospital-
ized patients with severe ARF; on patients receiving a
renal biopsy; or on cases of drug nephrotoxicity [3, 6,
11, 12]. In the general population, ARF in the ambu-
latory setting compromises 1% of all hospitalizations
[13]. ARF in this setting is usually uncomplicated and of
good prognosis [13]. The incidence and causes of ARF
and its impact on clinical outcomes has not been de-
scribed in ambulatory HIV-infected patients. This study
aims to make these determinations among HIV-infected
individuals receiving primary HIV care and participat-
ing in a large observational prospective clinical cohort
study.
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METHODS
Study design and population
This study relied on the University of North Car-
olina Center for AIDS Research HIV/AIDS Research
and Clinical Cohort Study (UNC CFAR Cohort Study),
which has been enrolling all HIV-infected patients seen
at a university-based infectious diseases clinic since
January 2000. All HIV-infected patients 18 years of age
or older are eligible to participate in the prospective co-
hort study. Written informed consent is obtained from all
participants, with less than 2% of patients approached de-
clining participation. Clinical and demographic data are
collected at enrollment and prospectively every 6 months
through standardized medical records abstractions. Addi-
tional clinical, laboratory, and demographic information
is available through daily electronic transfer from existing
institutional databases. For this study all patients seen at
the clinic between January 1, 2000 and December 31, 2002
and providing written informed consent to participate in
the UNC CFAR Cohort Study were included. Patients
on chronic dialysis within 3 months of enrollment due
to conditions unrelated to ARF were excluded. For this
study, we defined baseline as the patients’ first visit on or
after January 1, 2000 but prior to December 31, 2002, and
we followed all patients prospectively through December
31, 2002.
The study was approved by the Institutional Review
Board of the University of North Carolina (UNC) School
of Medicine.
Outcome measure
ARF was defined as sustained (over 2 days) increase in
serum creatinine of 0.5 mg/dL for patients with baseline
serum creatinine level less than 2.0 mg/dL, 1.0 mg/dL for
patients with baseline level of 2.0 mg/dL to 4.9 mg/dL,
and 1.5 mg/dL for patients with a baseline level equal to
or greater than 5.0 mg/dL [14]. The number of episodes of
ARF per patient was recorded and the events were con-
firmed by additional medical chart review performed by
the principal investigator on this study (N.F.). Underlying
clinical conditions at the time of the ARF event were re-
viewed in order to determine the potential causes of ARF.
ARF events were categorized as prerenal, intrinsic renal,
postrenal (obstructive), or unknown. Events were consid-
ered prerenal if they were (1) associated with diarrhea,
nausea, vomiting, congestive heart failure, cirrhosis, pan-
creatitis, infection, hypotension, or orthostasis; and (2)
renal function improved with hydration. ARF episodes
not improving within 24 hours with hydration were de-
fined clinically as ATN. Ischemic or nephrotoxic ATN
was defined based on the clinical history and drug expo-
sure. ARF associated with skin rash or fevers and urine
or blood eosinophils in a patient taking a drug known
to induce the disease was considered as being caused by
interstitial nephritis. Patients with ARF and findings of
thrombocytopenia and fragmented red blood cells on pe-
ripheral blood smear with or without neurologic symp-
toms were diagnosed with thrombotic microangiopathy
[thrombotic thrombocytopenic purpura or hemolytic ure-
mic syndrome (TTP-HUS)]. ARF due to urologic ob-
structions or drug induced crystalluria were considered
postrenal ARF. Renal and patient survival at 30 days of
the ARF event was recorded when available.
Comorbidities definitions and laboratory data
All laboratory tests were performed by the Univer-
sity of North Carolina Hospital Central Laboratory. CD4
cell counts, HIV RNA levels, and serum creatinine mea-
surements were available prospectively from baseline
throughout the period of observation. For baseline values
we relied on the most proximal measure available within
3 months of the baseline visit. HIV RNA levels were
based on the standard and ultrareverse transcriptase-
polymerase chain reaction (RT-PCR) assays (Roche Am-
plicor HIV-1 Monitor Assay) (Roche Molecular Systems,
Branchburg, NJ, USA). Hepatitis B coinfection (HBV)
was based on a positive serum hepatitis B surface antigen
(HBsAg) and/or hepatitis Be antigen (HBeAg). HCV
status was based on the presence of positive serum hep-
atitis C antibody (Ortho-Clinical Diagnostic, Raritan, NJ,
USA) or detectable HCV RNA. Renal function was es-
timated based on the Modification of Diet in Renal Dis-
ease (MDRD) modified formula [15]. Comorbidities such
as chronic hypertension and diabetes mellitus were di-
agnosed by the attending physician and based on the
medical chart reviews. AIDS-defining clinical conditions
were defined using the 1993 United States Center for
Disease Control and Prevention revision of case def-
inition of AIDS [16]. HAART was defined based on
published United States guidelines as (1) at least one
protease inhibitor (PI) or one nonnucleoside reverse
transcriptase inhibitor (NNRTI) in combination with two
or more nucleoside/nucleotide reverse transcriptase in-
hibitors (NRTI); or (2) one NRTI in combination with at
least one PI and at least one NNRTI; or (3) an abacavir-
containing regimen of three or more NRTIs in the ab-
sence of both PIs and NNRTIs [17, 18].
Statistical analysis
For descriptive analyses, means, standard deviation,
and frequencies were measured, as appropriate. Crude
ARF incidence rates with 95% confidence intervals (CI)
were estimated relying on a Poisson distribution by di-
viding the number of events by person-time at risk. To
compare patients with and without ARF, we relied on
t-tests or Pearson’s chi-square test. Analyses were per-
formed using 8.1 SAS Statistical Package (SAS Institute,
Cary, NC, USA).
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Table 1. Demographic and clinical characteristics of ambulatory human immunodeficiency virus (HIV)-infected patients with and without acute
renal failure (ARF), 2000–2002, North Carolina
All patients ARF Without ARF
(N = 754) (N = 71) (N = 683) P valuea
Male number (%) 510 (68) 57 (80) 453 (66) 0.02
Age years
17–39 376 (50) 31 (44) 345 (51)
40–59 356 (47) 38 (54) 318 (47) 0.75
60–71 22 (3) 2 (3) 20 (3)
Race number (%)
White 255 (34) 23 (32) 232 (34)
Black 461 (61) 44 (62) 417 (61) 1.00
Other 38 (5) 4 (6) 34 (5)
Hypertension number (%) 126 (17) 9 (13) 117 (17) 0.41
Diabetes mellitus number (%) 47 (6) 5 (7) 42 (6) 0.79
Hepatitis B number (%) 46 (6) 6 (8) 40 (6) 0.44
Hepatitis C number (%) 160 (21) 26 (37) 134 (21) 0.004
AIDS-defining illness number (%) 77 (10) 23 (32) 54 (8) <0.0001
HAART ever number (%) 540 (68) 62 (87) 452 (66) <0.0001
Serum creatinine number (%)
<1.2 710 (95) 69 (97) 641 (85)
≥1.2 40 (5) 2 (3) 38 (6) 0.83
CD4 cell count (cells/mm3) number (%)
<200 214 (29) 39 (57) 175 (27) <0.0001
≥200 515 (71) 30 (43) 485 (73)
HIV RNA (copies/mL) number (%)
<10,000 433 (62) 24 (36) 409 (64) <0.0001
10,000–30,000 64 (9) 9 (14) 55 (9)
>30,000 204 (29) 33 (50) 171 (27)
Abbreviations are: AIDS, acquired immunodeficiency syndrome; HAART, highly active antiretroviral therapy.
at test or Pearson’s chi-square test, comparing ARF with non-ARF.
RESULTS
Of 768 patients eligible to participate in this study, 2%
(N = 14) were excluded because they were on chronic
dialysis. On average, patients were 40 years of age (SD
= 9), 61% were blacks, and 32% were women (Table 1).
At enrollment, 17% of patients had hypertension; 6%
diabetes mellitus; 6% HBV; and 21% HCV. Serum crea-
tinine was 1.2 mg/dL or higher at baseline (enrollment)
in 5% of patients. Only 3% of patients had a glomeru-
lar filtration rate (GFR) lower than 60 mL/min/1.73 m2
at baseline, estimated by the modified MDRD for-
mula. At enrollment, 29% of patients had a CD4 count
<200 cells/mm3, 38% had an HIV RNA level ≥10,000
copies/mL, and 10% had prior AIDS-defining clinical
condition. The most common AIDS-defining illnesses
were esophageal candidiasis, Cryptococcus meningitis,
Pneumocystis carinii pneumonia, and Mycobacterium
avium complex or Mycobacterium kanasii-disseminated
disease. Approximately 70% of the patients had received
some HAART therapy.
One-hundred eleven episodes of ARF occurred among
71 subjects, with an incidence rate of 5.9 per 100 person-
years (95% CI 4.9, 7.1). ARF was more common among
men, patients with CD4 cell counts <200 cells/mm3, and
HIV RNA levels >10,000 copies/mL (Table 1). In addi-
tion, patients with ARF were more likely to have had an
AIDS-defining clinical condition, HCV coinfection, and
to have received HAART. HIV RNA level was higher
among those developing ARF compared to those with-
out ARF (mean log10 HIV RNA 4.2 ± 1.3 versus 3.4 ± 1.3,
respectively) (P < 0.0001). No differences were observed
between those with and without ARF by age, race, serum
creatinine, HBV coinfection, history of hypertension, or
diabetes mellitus. Median baseline serum creatinine was
0.8 mg/dL (interquartiles 0.7 and 0.9) for patients devel-
oping or not ARF. In addition, the majority of patients
developing ARF had a serum creatinine below 1.2 mg/dL
(Table 1).
Most (N = 77) (71%) ARF events were community-
acquired and 64% of these required hospitalizations for
treatment. Patients were hospitalized for a median of
4 days (range 1 to 51 days). ARF was the main cause
of hospitalization in 20 of 49 cases (41%) and the only
cause of admission in 15 of 49 cases (31%). The most
common mechanisms of ARF were prerenal and intrin-
sic renal events (Table 2). Diarrhea, nausea and vomiting,
liver failure, and infections were the most common causes
of prerenal states. Ischemia or noncontrast drug nephro-
toxicity accounted for the majority of the intrinsic renal
ARF. Only two cases of TTP-HUS were identified. Ob-
structive ARF was mainly due to drug crystalluria from
indinavir treatment.
Just over one half (N = 58) (52%) of all ARF events
were associated with infections, and 76% of these infec-
tions were AIDS-defining clinical conditions. The most
common sites of infections were central nervous system
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Table 2. Etiology of acute renal failure (ARF) in ambulatory human
immunodeficiency virus (HIV)-infected patients, 2000–2002, North
Carolina
ARF eventsa % by
Causes Number (%) subgroup
Prerenal 43 (38)
Diarrhea, nausea, vomiting, 18 42
dehydration
Heart failure 2 5
Cirrhosis or hepatorenal 9 21
syndrome
Pancreatitis 2 5
Adrenal insufficiency 1 2
Sepsis or infection 10 23
Erythroderma 1 2
Renal 48 (46)
Acute tubular necrosis
Ischemic 22 46
Nephrotoxic
Drugs 17 35
Radiocontrast 2 4
Interstitial nephritis 5 10
Thrombotic thrombocytopenic purpura- 2 4
hemolytic uremic syndrome
Obstructive 9 (7)
Kidney stones 2 22
Crystalluria 6 67
Gross hematuria 1 11
Unknown 11 (9)
aSeventy-one patients with 111 episodes of ARF.
(meningitis, encephalitis) (N = 16), lung (pneumonia,
lung abscess) (N = 17), bacteremia or endocarditis (N =
9), gastrointestinal (esophagitis, gastroenteritis, pancre-
atitis, cholangitis) (N = 6), skin (abscess) (N = 3),
and other sites (N = 7). The most common pathogens
were Cryptococcus neoformans, Pneumocystis carinii,
Cytomegalovirus, Herpes simplex, Mycobacterium tuber-
culosis, Mycobacterium avium complex, Mycobacterium
kanasii, and Staphylococcus aureus.
Drugs were associated with 32% (N = 36) of all events
and caused ATN, interstitial nephritis, crystalluria with
obstruction or prerenal states due to gastrointestinal
symptoms leading to dehydration. The most commonly
associated drugs were antibiotics, amphotericin B (N =
14), cotrimetoxazole (N = 2), aminoglycosides (N = 2),
capreomycin (N = 1), oxacillin (N = 1) and vancomycin
(N = 1); antiretroviral agents, indinavir (N = 6), tenofovir
(N = 2) and nevirapine (N = 1); analgesics, nonsteroidal
anti-inflammatory and cyclooxygenase-2 inhibitors (N =
3); radiologic contrast (N = 2); and lithium (N = 1). Crys-
talluria and microscopic hematuria were present in all pa-
tients with indinavir-induced ARF, and one patient had
also sterile pyuria. Two patients using tenofovir devel-
oped ATN in the absence of other obvious precipitating
factors for ARF. A patient taking nevirapine presented
with fevers, rash, eosinophilia, and ARF which was at-
tributed to interstitial nephritis. ARF and other symp-
toms resolved with the discontinuation of the drug.
Repeat episodes of ARF were more frequently ob-
served among patients with more advanced HIV disease.
Sixty-nine episodes of ARF occurred among 39 patients
with CD4 cell counts <200 cells/mm3, in comparison to
40 ARF events occurring among 30 patients with CD4
cell counts ≥200 mm3 (P < 0.001). One patient without
a recent CD4 cell count had two episodes of ARF. In ad-
dition, patients with low CD4 cell counts more often had
ATN and were less likely to have prerenal causes of ARF
compared to those with high CD4 cell counts, although
the trend was not statistically significant (48% versus 35%
for intrinsic ARF (P = 0.23) and 36% versus 45% for pre-
renal ARF (P = 0.42) contrasting patients with CD4 cell
counts <200 versus ≥200 cells/mm3, respectively). Liver
failure was the underlying cause of ARF in 10% of all
ARF events, and occurring predominantly among HCV
coinfected patients (90%). Liver failure accounted for
18% of the ARF events in patients with HCV infection
but only 2% of those without it (P < 0.01). None of the
patients with HBV infection experienced ARF.
Five patients required dialysis: two patients with TTP-
HUS, one with lithium overdose and ARF, one with hep-
atorenal syndrome, and one with ischemic ATN due to
sepsis. Only the patient with lithium toxicity recovered
renal function. All other patients not requiring dialysis
recovered renal function to baseline levels. The median
peak serum creatinine was 4.6 mg/dL (range 2.6 to 5.7)
for patients requiring dialysis and 2.1 mg/dL (range 1.1
to 7.3) for those not requiring dialysis (P < 0.001). For
patients not requiring dialysis, the median highest serum
creatinine was 2.0 mg/dL (range 1.1 to 7.3) and 2.3 mg/dL
(range 1.1 to 7.1) for those developing ARF in the out-
patient setting and those in the hospital, respectively.
Two patients had a renal biopsy. One patient presented
with renal dysfunction, sterile pyuria, microscopic hema-
turia, and indinavir crystalluria. Renal biopsy showed
indinavir-induced crystal intratubular obstruction. A pa-
tient with sepsis had renal biopsy findings of ATN. Both
patients recovered renal function to baseline levels. Three
patients requiring dialysis died within 30 days of the ARF
event, without recovering renal function. One patient
died due to complication related to TTP-HUS, one due
to sepsis, and one due to hepatorenal syndrome.
DISCUSSION
In this large prospective cohort of ambulatory HIV-
infected patients receiving primary HIV care, we
observed a high incidence rate of ARF events. ARF oc-
curred more often in men, HCV coinfected patients, and
individuals with more advanced HIV disease, including
patients with lower CD4 cell counts, higher HIV RNA
levels, and a prior AIDS-defining clinical condition. In
addition, patients with ARF were more likely to have
received HAART, likely related to their more advanced
1530 Franceschini et al: Acute renal failure and HIV
HIV disease. Race was not associated with increased in-
cidence rate of ARF, in contrast to chronic kidney disease
which has been mainly described in African Americans
[19].
Infections have been considered a major cause of se-
vere ARF in studies of HIV-infected patients [1, 3].
Among a sample of patients with advanced HIV dis-
ease progression, Rao and Friedman [3] observed half
of the patients presenting with ARF received a diagno-
sis of sepsis. Similarly, in our study, 52% of the ARF
events were associated with an infection, the majority
of which were AIDS-defining clinical conditions. In ad-
dition, drug nephrotoxicity frequently resulted from the
treatment of chronic fungal and bacterial infections in
immunocompromized patients. However, our study dif-
fered from prior studies by including mainly ambulatory
patients, the majority of whom had not had a prior AIDS-
defining clinical condition. Therefore, our results reveal
that infectious diseases and particularly opportunistic in-
fections are still a common underlying cause of ARF in
HIV-infected patients in the post-HAART era.
HCV is increasingly an important cause of morbidity
and mortality among HIV-infected patients [20–22]. A
recent study has shown an increase in the hospitalization
rates due to liver disease among HIV-infected women
[9], exceeding the rates of hospitalization due to AIDS-
defining conditions. ARF is a well-recognized complica-
tion of cirrhosis and liver failure in the general population
[13, 14]. Decreased renal perfusion due to aggressive use
of diuretics, ATN due to infections or use of nephrotoxic
antibiotics, as well as hepatorenal syndrome are some of
the mechanisms leading to ARF in these patients. HCV
coinfection occurs in 15% to 30% of all HIV-infected pa-
tients in the United States [23]. Despite the high preva-
lence of HIV-HCV coinfection [23], liver disease has not
been considered an important cause of ARF in prior stud-
ies of HIV-infected patients [24]. In our study, ARF due
to cirrhosis and liver failure accounted for approximately
20% of the cases of ARF among HIV-HCV coinfected
patients.
Drugs caused one third of all ARF events. Antiretro-
viral drugs were responsible for only few events but com-
promised two thirds of all cases of obstructive ARF.
Indinavir, tenofovir, and nevirapine were the only an-
tiretroviral drugs clearly associated with ARF in this
cohort. Indinavir treatment has been associated with crys-
talluria, nephrolithiasis, interstitial nephritis, and sterile
leukocyturia with renal dysfunction [25–28]. In our study,
all cases of indinavir-associated ARF were due to crys-
talluria and were obstructive in nature. Tenofovir, a nu-
cleotide reverse transcriptase inhibitor, was associated
with ATN in two patients. Several recent studies have
described renal proximal tubular toxicity in patients tak-
ing tenofovir. The most common presentation is Fanconi
syndrome [29] but cases of ARF due to ATN have been
also described [30, 31]. A patient receiving nevirapine
had ARF due to allergic interstitial nephritis. His symp-
toms and the ARF resolved with discontinuation of the
drug. Cutaneous allergic reaction is the most common ad-
verse event with nevirapine but kidney dysfunction has
not been frequently reported [32]. A recent study has re-
ported rash, fevers, eosinophilia, liver abnormalities, and
kidney dysfunction in a pregnant HIV-infected women
using nevirapine, findings similar to our patient’s presen-
tation [33]. In summary, ARF due to antiretroviral ther-
apy was usually reversible, uncomplicated, and in case of
indinavir an important cause of obstruction.
Two patients developed TTP-HUS in our study.
Thrombotic microangiopathies are unusual causes of
ARF in the general population. Several studies have de-
scribed occurrence of TTP-HUS in hospitalized HIV-
infected patients, or those undergoing a renal biopsy [6,
34]. In one study, among patients with advanced HIV
disease progression presenting with acute or rapidly pro-
gressive renal failure, TTP-HUS compromised 35% of
the ARF events, most of which were confirmed by a re-
nal biopsy [6]. In a study of renal biopsies, two of 17 HIV
patients had TTP-HUS in postmortem diagnosis, both
with very advanced immunosuppression [34]. Other large
studies of ARF, including patients without HIV infection,
have described few or no cases of TTP-HUS [3, 14]. In our
study, one patient presenting with TTP-HUS had a low
CD4 cell count but another had a normal CD4 cell count
and no prior history of an AIDS-defining clinical condi-
tion. Both patients required dialysis and did not recover
renal function, and one died. Prior studies of TTP-HUS
have also described high morbidity and mortality of the
disease in HIV-infected patients [1].
We relied on the definition of ARF developed by Nash,
Hafeez, and Hou [14] in order to identify mild to severe
cases of ARF in a large cohort of ambulatory patients.
Therefore, it is possible that we missed some cases of
ARF with lower increases in serum creatinine, although
the clinical relevance of such mild ARF is unclear. In ad-
dition, ARF due to rapid progressive glomerulonephri-
tis was not included in this analysis. All cases had their
medical charts reviewed by a trained nephrologist (N.F.)
to confirm the diagnosis and identify the etiology of the
ARF episode. However, we cannot rule out some mis-
classification as this study was limited by a reliance on
available clinical data.
This is the first study to determine the incidence of
mild to severe ARF in a large cohort of HIV-infected
ambulatory patients in the HAART era. Including pa-
tients at all stages of HIV disease progression allowed us
to identify new risk factors for ARF occurring in the era
of potent antiretroviral therapy use. As expected, preva-
lent comorbidities such as chronic liver disease due to
HCV are emerging causes of kidney dysfunction, includ-
ing ARF, among HIV-infected patients.
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CONCLUSION
ARF is a common condition in HIV-infected patients
receiving primary outpatient HIV care. Immunosuppres-
sion and infections remain important underlying condi-
tions causing ARF among HIV-infected patients, with
liver disease being the leading cause of ARF among pa-
tients with HIV-HCV coinfection.
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